TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00198978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone / Prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Colony-Stimulating Factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDARAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depocyte

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Study: NCT01318265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
Description: Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
Study: NCT04470622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant injectable emulsion
Description: Aprepitant injectable emulsion, once daily (QD) for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline Placebo, once daily (QD) for 14 days.
Study: NCT02796898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM88 (Cohort 1)
Description: * Tyrosine Isomers - 230 mg qd~* Phenytoin - 50 mg qd.~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM88 (Cohort 2)
Description: * Tyrosine Isomers - 460 mg (230 mg bid)~* Phenytoin - 50 mg qd~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd
Study: NCT01070277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole and Albendazole
Description: Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days
Study: NCT00399490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 50 mcg/kg
Study: NCT00056459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatalanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vatalanib
Study: NCT02084979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telepsychiatry evaluation
Description: telepsychiatry evaluation and consultation to primary care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telepsychiatry evaluation
Description: telepsychiatry evaluation and consultation to primary care
Study: NCT01992770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hierarchical graded exposure
Description: Individual Behavioural goal identification, depending on risk profile~(1a). Catastrophising and/or fear-avoidance (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded activity
Description: Individual Behavioural goal identification, depending on risk profile~(1b) Graded activity;(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercises
Description: Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercises
Description: Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
Study: NCT00197184

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix™ Adult
Description: Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix™ Junior
Description: Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
Study: NCT01652261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD + FDG-PET/CT Scan treatment adaptation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPPesc
Study: NCT00823082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Description: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
Study: NCT03452917

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 patients will 2 ml of normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite 45 mg
Description: 500 patients will receive 45 mg IV sodium nitrite

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite 60 mg
Description: 500 patients will receive a dose of 60 mg IV sodium nitrite
Study: NCT01316822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-382, cFMS inhibitor; oral
Description: multiple dose, escalating
Study: NCT00174993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
Study: NCT03668145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation or placebo infusion via peripheral vein
Description: 0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: mesenchymal stem cell transplantation or placebo infusion via peripheral vein
Description: 0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
Study: NCT03473925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: Oral capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT01987089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
Study: NCT03051100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180mg
Description: bempedoic acid 180 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: atorvastatin 20 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01207687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02045342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: Ingest 500ml (1g/kg) prior to metabolic measures.
Study: NCT01652261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEACOPPesc
Study: NCT03118765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP304 (tiotropium bromide) Inhalation Solution
Description: Once daily (QD) oral inhalation using a nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP304 (tiotropium bromide) Inhalation Solution
Description: Once daily (QD) oral inhalation using a nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP304 (tiotropium bromide) Inhalation Solution
Description: Once daily (QD) oral inhalation using a nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP304 Placebo Inhalation Solution
Description: Once daily (QD) oral inhalation using a nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva® Respimat® inhalation spray
Description: Once daily (QD) oral inhalation
Study: NCT00944385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ulinastatin
Description: Administer 30000U/ulinastatin. Comparison of different dosages of drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Administer 30000U/ulinastatin. Comparison of different dosages of drug.
Study: NCT04515511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4% gelatin
Description: Pulmonary artery catheter insertion is prepared before fluid challenge. Baseline hemodynamic value and each time after 5 sequential intravenous boluses of 100 mL colloid are recorded.
Study: NCT04528277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine plus isoniazid
Description: receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
Study: NCT00056082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Celecoxib daily for 12 months
Study: NCT03001011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate (GZ419831)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02942173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45RA-depleted peripheral blood mononuclear cells
Description: Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
Study: NCT02219295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sweet block
Description: oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sweet block
Description: oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sweet block
Description: oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bitter block
Description: oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
Study: NCT02045342

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate drink
Description: Ingest 500ml (1g/kg) prior to metabolic measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ingest 500ml of placebo prior to metabolic measures.
Study: NCT02219295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bitter block
Description: oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bitter block
Description: oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: umami-block
Description: oral application of umami substances as glutamate with and without IMP, collection of blood samples as above

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: umami-block
Description: oral application of umami substances as glutamate with and without IMP, collection of blood samples as above

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: umami-block
Description: oral application of umami substances as glutamate with and without IMP, collection of blood samples as above

Intervention type: OTHER
Group type: OTHER
Intervention: gastroscopy
Description: gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
Study: NCT00947245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, 300 mg, Single Dose, One day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, 900 mg, Single Dose, One day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, ≤1200 mg, Single Dose, One day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, 300 mg, Every 12 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, 900 mg, once daily 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Single Dose, One day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Single Dose, One day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Single Dose, One day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Every 12 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Once Daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Every 12 hours or once daily, 14 days
Study: NCT02828228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 1200 IU
Description: Vitamin D 1200 IU once a day for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once a day for 26 weeks
Study: NCT04372212

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia sac inversion and Snaring
Description: Vertical trans umbilical 5-mm incision \[Point A\] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia sac inversion and Snaring
Description: Vertical trans umbilical 5-mm incision \[Point A\] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port.
Study: NCT00709475

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT03810664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatrogon
Description: A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatrogon
Description: A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
Study: NCT03974581

Intervention type: OTHER
Intervention: Primary percutaneous coronary intervention
Description: Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.

Intervention type: OTHER
Intervention: Pharmacoinvasive strategy
Description: Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
Study: NCT01343628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Atomoxetine, Placebo
Description: 16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
Study: NCT02633761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: 200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg
Description: Buccal misoprostol 200mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol 200mcg
Description: Buccal misoprostol 200mcg
Study: NCT01276028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture
Description: For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments.
Study: NCT02657083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Substance Administration Device
Description: 2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor Augmented Pump (SAP)
Description: 2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise